Macular Health / AMD
- Age-Related Eye Disease Study 2 (AREDS2) Research Group. JAMA 2013;309(19):2005-2015. doi: 10.1001/jama.2013.4997
Red Light Therapy (Photobiomodulation)
- U.S. Food and Drug Administration. De Novo Classification Request, Valeda Light Delivery System (DEN230083). Device type: light based device for dry age-related macular degeneration. Class II, 21 CFR 886.5520, product code SDE. FDA decision summary (PDF)
- Boyer D, Hu A, Warrow D, et al. Retina 2024;44(3). doi: 10.1097/IAE.0000000000003980 (LIGHTSITE III, 13-month results, sham-controlled RCT)
- Jaffe GJ, Boyer D, Hu A, et al. Retina 2026;46(5). doi: 10.1097/IAE.0000000000004822 (LIGHTSITE III, 24-month results)
- Chen KY, Lee HK, Chan HC, Chan CM. Ophthalmol Ther 2025;14(5). doi: 10.1007/s40123-025-01119-w (independent meta-analysis of 6 randomized studies: no significant benefit on acuity or structure)
- Grewal MK, Sivapathasuntharam C, Chandra S, et al. J Clin Med 2020;9(4):1001. doi: 10.3390/jcm9041001 (670 nm at home in intermediate AMD: no functional or structural change)
- Shinhmar H, Hogg C, Neveu M, Jeffery G. Sci Rep 2021;11:22872. doi: 10.1038/s41598-021-02311-1 (single 670 nm exposure, colour contrast thresholds)
- Ostrin LA, Schill AW. Ophthalmic Physiol Opt 2024;44(2). doi: 10.1111/opo.13272 (consumer red-light instruments exceeded exposure limits)
- Liu H, Yang Y, Guo J, Peng J, Zhao P. JAMA Ophthalmol 2023;141(7). doi: 10.1001/jamaophthalmol.2023.1548 (retinal damage after repeated low-level red light)
Dry Eye
- Semp DA, Beeson D, Sheppard AL, Dutta D, Wolffsohn JS. Clin Optom (Auckl) 2023;15:9-27. doi: 10.2147/OPTO.S350185 (systematic review — lipid-containing artificial tears benefit evaporative dry eye)
Floater Supplements
- Ankamah E, Green-Gomez M, Roche W, et al. TVST 2021;10(12):19. doi: 10.1167/tvst.10.12.19
- Takeuchi M, Shieh P-C, Horng C-T. Appl Sci 2020;10(17):5901. doi: 10.3390/app10175901
- Hammer M, Muuss M, Schickhardt S, et al. IOVS 2024;65(3):36. doi: 10.1167/iovs.65.3.36
- Malandrini D, et al. Vision 2025;9(4):98. doi: 10.3390/vision9040098
- Du J, Sabbagh O, Do BK, et al. J Vitreoretin Dis 2025;9(6):831-835. doi: 10.1177/24741264251364819
Floater Surgery & Laser (YAG Vitreolysis / Vitrectomy)
- Shah CP, Heier JS. JAMA Ophthalmol 2017;135(9):918-923. doi: 10.1001/jamaophthalmol.2017.2388 (YAG vitreolysis vs sham RCT)
- Delaney YM, Oyinloye A, Benjamin L. Eye 2002;16(1):21-26. doi: 10.1038/sj.eye.6700026 (YAG vitreolysis & PPV)
- Kokavec J, Wu Z, Sherwin JC, Ang AJS, et al. Cochrane Database Syst Rev 2017;(6). doi: 10.1002/14651858.CD011676.pub2 (Cochrane review: YAG vs PPV)
- Sebag J, Yee KMP, Nguyen JH, et al. Ophthalmol Retina 2018;2(9):881-887. doi: 10.1016/j.oret.2018.03.011 (limited vitrectomy, 195 eyes)
- Schulz-Key S, Carlsson JO, Crafoord S. Acta Ophthalmol 2011;89(2):159-165. doi: 10.1111/j.1755-3768.2009.01682.x (long-term PPV outcomes, 73 eyes)
Treatments We're Watching
- Falsini B, et al. Invest Ophthalmol Vis Sci 2010;51(12):6118-6124. doi: 10.1167/iovs.09-4995
- Piccardi M, et al. Evid Based Complement Alternat Med 2012;2012:429124. doi: 10.1155/2012/429124
- Broadhead GK, et al. BMJ Open Ophthalmol 2024;9(1):e001399. doi: 10.1136/bmjophth-2023-001399
- Evans JR. Cochrane Database Syst Rev 2013. doi: 10.1002/14651858.CD001775.pub2
- Giannaccare G, et al. Mar Drugs 2020;18(5):239. doi: 10.3390/md18050239
- Canter PH, Ernst E. Surv Ophthalmol 2004;49(1):38-50. doi: 10.1016/j.survophthal.2003.10.006
- García-Bardera J, et al. Front Ophthalmol 2026. doi: 10.3389/fopht.2026.1812914
- Prinz J, et al. Pharmaceuticals 2023;16(5):762. doi: 10.3390/ph16050762
Macular Pucker / Epiretinal Membrane
- Mitchell P, et al. Ophthalmology 1997;104(7):1033-1040. doi: 10.1016/s0161-6420(97)30190-0 (Blue Mountains Eye Study)
- Fung AT, Galvin J, Tran T. Clin Exp Ophthalmol 2021. doi: 10.1111/ceo.13914 (ERM review)
- Diagnostics 2025;15(20):2596. doi: 10.3390/diagnostics15202596 (newer SR, OCTA biomarkers in idiopathic epiretinal membrane)
- Christodoulou E, et al. Ther Adv Ophthalmol 2020. doi: 10.1177/2515841420927133 (ILM peel meta-analysis)
- Song SJ, et al. Retina 2015;35(5):866-872. doi: 10.1097/IAE.0000000000000406 (vitrectomy prognostic factors)
High Eye Pressure / Glaucoma
- Kim J, Aschard H, Kang JH, et al. Ophthalmology 2021;128(6):866-876. doi: 10.1016/j.ophtha.2020.12.009 (caffeine & IOP, UK Biobank gene-diet study)
- J Curr Ophthalmol 2026. doi: 10.4103/joco.joco_43_26 (newer SR+MA, caffeine & IOP in healthy & glaucomatous populations)
- De Moraes CG, John SWM, Williams PA, et al. JAMA Ophthalmol 2022;140(1):11-18. doi: 10.1001/jamaophthalmol.2021.4576 (nicotinamide phase 2 RCT)
- Sherratt-Mayhew S, Bisp M, Page C, Koo WSV. Cureus 2026. doi: 10.7759/cureus.110196 (newer SR, nicotinamide & mean deviation in glaucoma)
- Hui F, Tang J, Williams PA, et al. Clin Exp Ophthalmol 2020;48(7):903-914. doi: 10.1111/ceo.13818 (nicotinamide crossover RCT)
- Steigerwalt RD Jr, Belcaro G, Morazzoni P, et al. Clin Ophthalmol 2010;4:471-476. doi: 10.2147/opth.s9899 (Mirtogenol + latanoprost)
- Jabbarpoor Bonyadi MH, et al. BMC Complement Altern Med 2014;14:399. doi: 10.1186/1472-6882-14-399 (saffron & IOP)
- Peritore G, et al. PLoS One 2023;18(10):e0291836. doi: 10.1371/journal.pone.0291836 (citicoline systematic review)
- Icel E, Akmaz O. Beyoglu Eye J 2026;11(1):1-12. doi: 10.14744/bej.2026.93709 (newer SR, citicoline in ophthalmology)
How We Monitor for Updates
We scan the internet and scientific journals every week for updates, corrections, and new research related to the studies we are following. If a link moves, a DOI is corrected, or a key paper is superseded, we update this page and note the change.